Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

PURPOSE: To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 43 patients with BRAF V600–mutant mCRC were treated with dabrafenib (150 mg twice...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Corcoran, Ryan B., Atreya, Chloe E., Falchook, Gerald S., Kwak, Eunice L., Ryan, David P., Bendell, Johanna C., Hamid, Omid, Messersmith, Wells A., Daud, Adil, Kurzrock, Razelle, Pierobon, Mariaelena, Sun, Peng, Cunningham, Elizabeth, Little, Shonda, Orford, Keith, Motwani, Monica, Bai, Yuchen, Patel, Kiran, Venook, Alan P., Kopetz, Scott
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2015
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669588/
https://ncbi.nlm.nih.gov/pubmed/26392102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.63.2471
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker